
Opinion|Videos|September 22, 2023
Luspatercept as a Treatment Option in MDS
Author(s)Jamie L. Koprivnikar, MD
Jamie L. Koprivnikar, MD, reviews luspatercept as a treatment option in myelodysplastic syndrome and the adverse events most frequently seen with her patients in clinical practice.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































